透析患者接种新型冠状病毒疫苗研究进展  

Research advances of SARS-CoV-19 vaccination for patients with chronic dialysis

作　　者：马雷雷 李静[1] 张莉[1] 支勇[1] 邢海涛[1] 姜晨[1] 杨洪涛[1] Ma Lei-lei;Li Jing;Zhang Li;Zhi Yong;Xing Hai-tao;Jiang Chen;Yang Hong-tao(Department of Nephrology,First Teaching Hospital,Tianjin University of Traditional Chinese Medicine,National Clinical Research Center for Chinese Medicine Acupuncture&Moxibustion,Tianjin 300380,China)

机构地区：[1]天津中医药大学第一附属医院肾病科,国家中医针灸临床医学研究中心,天津300380

出　　处：《临床肾脏病杂志》2023年第8期685-690,共6页Journal Of Clinical Nephrology

基　　金：国家自然科学基金项目(82004316,81973799)。

摘　　要：在严重呼吸窘迫综合征冠状病毒-2019流行期间,透析患者属于易感人群之一,并且一旦感染新型冠状病毒之后病死率明显升高。目前全球范围内已经研发出多种类型的新冠疫苗并已经完成多数人群接种,但由于透析患者的自身疾病特点,其接种疫苗之后的血清转化及免疫应答与健康人群有明显差异,本文总结了近年来发表的有关透析人群接种新冠疫苗之后的文献研究,以期为临床进一步制定透析患者接种新冠疫苗方案提供证据支持。During the pandemic of severe acute respiratory syndrome coronavirus-2019,chronic dialysis patients belong to one of vulnerable groups and have a higher mortality after infection.Currently several kinds of SARS-CoV-19 vaccines have been developed and most people have been vaccinated worldwide.The seroconversion status and immune response of dialysis patients after vaccination differ greatly from those of normal people because of their disease characteristics.This review summarized the latest researches on on-dialysis recipients of COVID-19 vaccine to provide evidence support for COVID-19 vaccinating for chronic dialysis patients.

关 键 词：肾透析 严重呼吸窘迫综合征冠状病毒-2019 疫苗 SARS-COVID-19 

分 类 号：R692.5[医药卫生—泌尿科学] R186[医药卫生—外科学]